Page 14 - LabMedya English - 04

/labmedya

014 HEALTH AND LABORATORY MAGAZINE

GIANT PARTNERSHIP FROM
NEW DRUG IN JANSSEN AND ABDİ İBRAHİM

PROSTATE CANCER
PHARMACEUTICAL COMPANY

BOĞAZIÇI UNIVERSITY, COLLEGE DE as Abdi İbrahim, they are
FRANCE AND FRENCH BIOTECHNOLOGY one of the biggest sup-
porters of the localization
COMPANY IPSEN COLLABORATED FOR in medicine and that they
A NEW TREATMENT AIMED AT THE COM- act with this responsibil-
PLETE DESTRUCTION OF TUMOR CELLS IN ity in all of their ongoing
investments as well as the
PROSTATE CANCER. investments they have
implemented. Stating
The executive director blocking it after binding. that they believe that
of the project is Assoc. This is a very new treat- localization is an extremely
Prof. Umut Şahin, Faculty ment concept. The andro- important driving force for
Member of the Molecular gen receptor is actually a Turkey to become a global
Biology and Genetics protein. The life and cycle player in medicine, Süha
Department of Boğaziçi of the cell depends on Taşpolatoğlu emphasized
University. The drug in different proteins. But all that they are proud to be
question will be the first proteins have a lifetime, the pioneer of this field
treatment developed in they are destroyed after a both in intellectual stage
this concept in the treat- while. This new drug also Janssen, a pharmaceuti- innovative treatments in and in practice and said:
ment of prostate cancer helps the cell turn to that cal company of Johnson & Turkey. We are engaged
in the world. destruction mechanism. Johnson, has joined forces in initiatives that aim to “Abdi İbrahim, which has
In other words, when the with the Turkish pharma- advance the government’s been operating in the phar-
Within the scope of the drug binds to the andro- maceutical sector for 106
ongoing project with the gen receptor, it destroys ceutical company Abdi policies towards the health years, has a determined
needs of the country’s
partnership of Boğaziçi the cell, and the prostate İbrahim. Within the scope stance to run ahead with its
University, College de cancer cells that depend of the partnership between people. The collaboration technologically equipped
France and international on it also die. What is Abdi İbrahim and Janssen, we established with Abdi facilities, strong human re-
biotechnology company exciting here is that only which has carried out about İbrahim within the scope of sources and investment in
Ipsen, the cell with cancer prostate cancer cells die, 40 million dollars of clinical localization is a concrete R&D but most importantly,
is targeted to be destr- the focus of the problem research in our country in step in this direction. We will our vision of supporting
cuted at all by applying a is destroyed, and while the last 10 years, it is aimed continue to bring innovative Turkey’s goal of becoming
new treatment method in doing so it does not harm to increase domestic drug treatments to Turkey by an active player in medi-
prostate cancer. Provid- other healthy cells”. production capacity and strengthening our existing cine. Our target in 2020 is
ing information about this competence. collaborations. Thanks to to grow further in the field
treatment, which is a first Stating that the drug to these new treatments, we of production service with
in the literature, Assoc. be developed will be ef- In the ceremony organized aim to change the course new collaborations and to
Prof. Şahin stated that fective on prostate cancer for the signature of the of serious diseases affect- become the production
prostate cancer ranks cells that do not respond partnership, the CEO ing patients in Turkey. base of international
second after lung cancer to current treatments, of Janssen Emerging “WE WILL INCREASE companies in Turkey. For
in men worldwide, and Şahin stated that the drug Markets, Luis Diaz Rubio, this purpose, we constantly
that it can be treated with will be the first treatment CEO of Janssen Turkey, COMPETITIVENESS OF strengthen our production
TURKEY IN THE GLOBAL
surgery but it is resistant developed in this concept Maria Fernando Prado and infrastructure and offer
to treatment at advanced in the treatment of pros- CEO Süha Taşpolatoğlu, MARKET” our standards that com-
stages and is prone to tate cancer in the world. representing Abdi İbrahim, In his speech at the cer- pete with the world to the
metastasis in early diag- Stating that the preclinical participated. emony, Janssen Turkey service of the companies
nosis. we cooperate with. We
studies of the drug are Speaking at the ceremony, General Manager Maria work with the target of
Therefore, expressing carried out with animal Janssen General Manager Fernanda Prado said being the best option for
that there is an important experiments and they of Emerging Markets, Luis the following regarding all our customers with our
need for targeted therapy are as productive as the Diaz Rubio, said that Turkey localization policies in production environments
in prostate cancer, Umut second generation drugs is an important country Turkey: “We took action to designed specifically for
Şahin said that they are in the market, Umut Şahin in the region with its improve Turkey’s domestic the needs. The production
developing a new treat- informed “In the most op- breakthroughs especially drug production capacity agreement we have with
ment that will be a first in timistic case, the drug will in the last 10 years and the and competence and to Janssen today for added
the literature in this field be available to humans treatments it provided. increase its competitive- value drugs is a natural
and continued: when all phase studies Rubio said: “We are one of ness in the global market.
are completed within 3-5 the companies that invest In our localization focus, our result of this effort and is
“We now plan to use a years. the most in R&D. We spend innovative drugs that will therefore extremely impor-
new treatment method in more than 20 percent of increase the international tant to us. We consider this
prostate cancer, which we As one of the scientists our global annual income competitiveness of Turkey agreement, which we have
have used and obtained who have been deemed on R&D investments. With in the treatment of cancer signed, as the first step of
successful results before worthy of research sup- our strategy of reaching and rare diseases will be our long-term collabora-
in two different types of port from Turkey within the needy of innovative included. I hope this new tion, and we hope to further
leukemia. We developed the scope of the Gilead action we have taken will develop this collaboration
a different drug that Sciences Turkey program medicines, as Johnson & bring success”. in the coming period. In
works based on the same that has been operating Johnson’s pharmaceutical the coming period, we will
treatment method. The in the field of biotechnol- company Janssen, we have “WE TARGET TO BE continue to develop similar
goal of our targeted drug ogy since 2013, Assoc. put 16 new molecules into AN ACTIVE PLAYER IN collaborations with the
is to bind to the androgen Prof. Umut Şahin has also the service of medicine DOMESTIC DRUGS” mission of being the driving
receptor and completely received the “The Ideas since 2009. We maintain force in Turkey’s growth
destroy it, rather than put into Practice” award. our trust and loyalty to Speaking at the ceremony, targets.
the country with our 20 CEO of Abdi İbrahim Süha
years of investments and Taşpolatoğlu stated that,